Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 2Malignant Solid Tumor 1Hepatitis C, Chronic 1Hepatitis C 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Ribavirin × 1 year × Clear all
NCT02771405 2026-04-13

FRI-STC

National Hepatology & Tropical Medicine Research Institute

Phase 3 Completed
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Hepatitis C, Chronic

NCT01309490 2025-07-29

Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients

Jewish General Hospital

Phase 1/2 Terminated
5 enrolled
Other solid neoplasm

Malignant Solid Tumor

NCT02940496 2025-07-15

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
15 enrolled 8 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡